Source study found

Story checked

Scientists find a bone-building switch that could fight osteoporosis | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-09-09

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Scientists find a bone-building switch that could fight osteoporosis | ScienceDaily

sciencedaily.com · 2026-09-09

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

3 supported
1 not covered

Open claim evidence

The source study

The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation

Signal Transduction and Targeted Therapy · 2025Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredThe story says AP503 increased bone strength in both healthy mice and mice with osteoporosis-like bone loss, and that the same treatment had previously been linked to stronger skeletal muscle.View evidenceHide evidence

Why this verdict

The profile supports AP503 effects in vivo and in an ovariectomy osteoporosis model, but at abstract depth it is unclear whether a separate healthy-mouse bone-strength experiment was performed or whether the in vivo enhancement was part of the OVX disease-model experiment. The claim that the same compound had previously been linked to stronger skeletal muscle is not present in the supplied abstract-level paper profile, so it cannot be verified from the supplied evidence.

Study evidence

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vivo (as stated in the abstract).

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

Study evidence

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) in an ovariectomy mouse model enhanced osteoblast function/differentiation and significantly alleviated osteoporosis in vivo (abstract statement).

“significantly alleviating osteoporosis in a mouse ovariectomy model.”

Claim 2 of 4SupportedResearchers at Leipzig University identified GPR133 as a target that appears to play an important role in keeping bones strong.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a role for GPR133/ADGRD1 in bone biology: mouse constitutive and osteoblast-specific loss of Gpr133/Adgrd1 produced an osteopenic/osteoporosis-like phenotype with reduced cortical bone mass/trabecular changes, attributed to impaired osteoblast function and increased osteoclast activity. The story’s hedged wording that GPR133 “appears” important for keeping bones strong is consistent with this mouse evidence.

Study evidence

Constitutive and osteoblast-specific Gpr133/Adgrd1 knockout in mice causes reduced cortical bone mass and altered trabecularization in femurs and vertebrae; this osteopenic phenotype is driven by impaired osteoblast function with secondary increases in osteoclast activity.

“Constitutive and osteoblast-specific knockouts of Gpr133/Adgrd1 in mice lead to reduced cortical bone mass and trabecularization in the femurs and vertebrae”

Study evidence

Loss of Gpr133/Adgrd1 in mice (constitutive and osteoblast-specific KO) produces reduced cortical bone mass and decreased trabecularization in femurs and vertebrae, an osteopenic phenotype that the authors ascribe to impaired osteoblast function with a secondary increase in osteoclast activity.

“This osteopenic phenotype in receptor-deficient mice is caused by impaired osteoblast function, which, in turn, promotes increased osteoclast activity.”

Claim 3 of 4SupportedAn experimental compound called AP503 significantly strengthened bones in mice by activating GPR133, which the story says boosts bone formation while slowing bone loss.View evidenceHide evidence

As statedsignificantly strengthened bones

Why this verdict

The abstract profile supports the core causal mouse-experiment claim: AP-970/43482503 (AP503) is described as a receptor-specific ligand activating GPR133/ADGRD1, enhancing osteoblast function/differentiation in vitro and in vivo, and significantly alleviating osteoporosis in an ovariectomy mouse model. The profile does not provide numeric effect sizes or exact bone-strength measurements at abstract depth, but the story’s causal framing is broadly aligned with the experimental intervention evidence in mice.

Study evidence

Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vitro.

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

Study evidence

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vivo (as stated in the abstract).

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

Claim 4 of 4SupportedThe researchers suggest GPR133 could be a potentially valuable target for future osteoporosis treatments, including osteoporosis associated with menopause.View evidenceHide evidence

Why this verdict

The profile supports a hedged future-treatment interpretation: the paper reports GPR133/ADGRD1 as involved in bone formation and shows AP503 significantly alleviated osteoporosis in an ovariectomy mouse model, which is commonly used for postmenopausal/menopause-associated osteoporosis. The story appropriately frames this as a potential future target rather than an established treatment.

Study evidence

“Constitutive and osteoblast-specific knockouts of Gpr133/Adgrd1 in mice lead to reduced cortical bone mass and trabecularization in the femurs and vertebrae”

Study evidence

“significantly alleviating osteoporosis in a mouse ovariectomy model.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The paper reports mechanistic activation involving PTK7 and mechanical forces, supported by in vitro stretch assays and an in vivo mechanical loading experiment.
The story presentation does not mention the PTK7 ligand/mechanical-force activation mechanism. This omission narrows the mechanistic context but does not directly reverse the main AP503/GPR133 story claims.
From In vitro cell stretch assays with PTK7 interaction testing; in_vivo_mechanical_loading
The paper reports a downstream cAMP-dependent β-catenin signaling mechanism for GPR133/ADGRD1-mediated osteoblast differentiation.
The story summarizes bone formation and bone-loss effects but does not include the cAMP/β-catenin pathway mechanism described in the abstract-level profile.
From in vitro pathway analysis

3 things the story did carry across

Mouse genetic loss-of-function evidence shows GPR133/ADGRD1 is required for normal bone formation and that receptor loss causes an osteopenic/osteoporosis-like phenotype.
AP503 pharmacologic activation of GPR133/ADGRD1 enhances osteoblast function/differentiation and alleviates osteoporosis in an ovariectomy mouse model.
Evidence is preclinical: mouse and in vitro evidence, with no direct human treatment trial evidence in the supplied profile.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalLoss of GPR133/ADGRD1 in mice causes an osteopenic/osteoporosis-like skeletal phenotype due to impaired osteoblast function with secondary increases in osteoclast activity.In vivo mouse genetic knockout skeletal phenotypingExpand

In plain English

Constitutive and osteoblast-specific loss-of-function of Gpr133/Adgrd1 in mice produces an osteopenic/osteoporosis-like skeletal phenotype characterized by reduced cortical bone mass and altered trabecularization in femora and vertebrae. The phenotype is attributed to impaired osteoblast function with secondary increases in osteoclast activity, supporting a physiological role for GPR133/ADGRD1 in promoting bone formation.

Key findings

Constitutive and osteoblast-specific Gpr133/Adgrd1 knockout in mice causes reduced cortical bone mass and altered trabecularization in femurs and vertebrae; this osteopenic phenotype is driven by impaired osteoblast function with secondary increases in osteoclast activity.

“Constitutive and osteoblast-specific knockouts of Gpr133/Adgrd1 in mice lead to reduced cortical bone mass and trabecularization in the femurs and vertebrae”

What this piece can’t prove

Evidence is derived from mouse knockout models; the abstract does not provide direct human experimental confirmation.

2 further details could not be confirmed from the summary.

2in vivo animalLoss of GPR133/ADGRD1 in mice causes an osteopenic/osteoporosis-like skeletal phenotype due to impaired osteoblast function with secondary increases in osteoclast activity.Expand

In plain English

The paper reports that constitutive and osteoblast-specific knockout of Gpr133/Adgrd1 in mice produces an osteopenic phenotype (reduced cortical bone mass and trabecularization in femurs and vertebrae) that the authors attribute to impaired osteoblast function, with a secondary increase in osteoclast activity.

Key findings

Loss of Gpr133/Adgrd1 in mice (constitutive and osteoblast-specific KO) produces reduced cortical bone mass and decreased trabecularization in femurs and vertebrae, an osteopenic phenotype that the authors ascribe to impaired osteoblast function with a secondary increase in osteoclast activity.

“This osteopenic phenotype in receptor-deficient mice is caused by impaired osteoblast function, which, in turn, promotes increased osteoclast activity.”

What this piece can’t prove

2 further details could not be confirmed from the summary.

3in vitroGPR133/ADGRD1 regulates osteoblast differentiation/function via combined activation by an endogenous ligand (PTK7) and mechanical forces (mechanosensitive activation).In vitro cell stretch assays with PTK7 interaction testingExpand

In plain English

The paper reports that in vitro cell stretch assays demonstrate GPR133/ADGRD1 regulates osteoblast differentiation and function via a combined activation mechanism that involves interaction with the endogenous ligand PTK7 together with mechanical stimulation.

Key findings

Stretch assays performed in vitro are reported to show that GPR133/ADGRD1 regulates osteoblast differentiation/function through a combined activation mechanism requiring interaction with PTK7 and mechanical forces.

“At the molecular level, GPR133/ADGRD1 regulates osteoblast function and differentiation through a combined activation mechanism involving interaction with its endogenous ligand, protein tyrosine kinase 7 (PTK7), and mechanical forces.”

What this piece can’t prove

The mechanistic claim (combined activation by PTK7 and mechanical force) is stated but the abstract does not detail causality tests (necessity/sufficiency).

3 further details could not be confirmed from the summary.

4in vivo animalGPR133/ADGRD1 regulates osteoblast differentiation/function via combined activation by an endogenous ligand (PTK7) and mechanical forces (mechanosensitive activation).in vivo mechanical loadingExpand

In plain English

An in vivo mechanical loading experiment in mice was performed and reported as evidence that mechanical forces activate GPR133/ADGRD1 in a living system, affecting osteoblast function and differentiation and supporting a combined activation mechanism with the endogenous ligand PTK7.

Key findings

An in vivo mechanical loading experiment indicates that mechanical forces can activate GPR133/ADGRD1 in mice and that this activation affects osteoblast function and differentiation.

“and in vivo via a mechanical loading experiment.”

What this piece can’t prove

2 further details could not be confirmed from the summary.

5in vitroGPR133/ADGRD1-mediated osteoblast differentiation is driven by cAMP-dependent activation of β-catenin signaling.in vitro pathway analysisExpand

In plain English

The abstract reports that, in vitro, GPR133/ADGRD1 promotes osteoblast differentiation via a mechanism that requires cAMP-dependent activation of β-catenin signaling.

Key findings

GPR133/ADGRD1-mediated osteoblast differentiation is driven by cAMP-dependent activation of the β-catenin signaling pathway (reported from in vitro analyses).

“Further in vitro analysis shows that GPR133/ADGRD1-mediated osteoblast differentiation is driven by cAMP-dependent activation of the β-catenin signaling pathway.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

6in vitroPharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function/differentiation and alleviates osteoporosis in an ovariectomy mouse model.In vitro ligand agonism to assess osteoblast differentiation/functionExpand

In plain English

In vitro pharmacologic activation of the adhesion GPCR GPR133/ADGRD1 with the receptor-specific agonist AP-970/43482503 (AP503) enhanced osteoblast function and differentiation in assays reported in the paper abstract.

Key findings

Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vitro.

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

What this piece can’t prove

Summary is based solely on the paper abstract; methodological and numerical details of the in vitro experiments are not provided there.

2 further details could not be confirmed from the summary.

7in vivo animalPharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function/differentiation and alleviates osteoporosis in an ovariectomy mouse model.in vivo pharmacologic administrationExpand

In plain English

The paper reports that pharmacologic activation of the adhesion GPCR GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vivo (abstract statement). The abstract also states AP503 alleviates osteoporosis in an ovariectomy (OVX) mouse model, but the unit focuses on the claim of in vivo enhancement of osteoblast function/differentiation separate from the disease-model efficacy.

Key findings

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vivo (as stated in the abstract).

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

What this piece can’t prove

Unspecified whether the in vivo AP503 experiment was performed in healthy mice or as part of the OVX model.

3 further details could not be confirmed from the summary.

8in vivo animalPharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function/differentiation and alleviates osteoporosis in an ovariectomy mouse model.in vivo animal OVX pharmacologic interventionExpand

In plain English

In an ovariectomy (OVX) mouse model of osteoporosis, pharmacologic activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhanced osteoblast function and differentiation in vivo and 'significantly alleviated osteoporosis' relative to controls (abstract statement).

Key findings

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) in an ovariectomy mouse model enhanced osteoblast function/differentiation and significantly alleviated osteoporosis in vivo (abstract statement).